posted                      

VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - Robert Rieveley, President of Biotech Holdings (the "Company", TSX-V: BIO.V; OTC BB: BIOHF) announced today that the Company is opening an office in Mexico to coordinate sales and marketing for the Latin American region. "I am pleased to announce that the Company is opening an office in Mexico City. Our Vice-President of Latin American Operations, Mr. Luis Manuel, will be based at our new office. Mr. Manuel is co-ordinating the launch of Sucanon in Mexico and will be responsible for overseeing sales, marketing and supply in the very important Mexican market," Mr. Rieveley said. "At the same time, Mr. Manuel will co-ordinate all requirements for launching Sucanon in Peru this fall and will be responsible for making regulatory applications for Sucanon in a number of other Spanish-speaking markets, including Argentina, Chile and Venezuela," Mr. Rieveley added. "As well as being a lawyer, Mr. Manuel has a strong business management background. This combination we believe makes him well-suited to managing the launch of Sucanon in Mexico and working with regulators and distribution partners in other Latin American markets," Mr. Rieveley said. "The launch of Sucanon in Mexico is imminent, but has been held up while some additional work is done on our infomercial, which is being produced in Colombia. After viewing the infomercial, we decided that the spokesperson used was simply too young and a more mature spokesperson was needed to present Sucanon in the infomercial and television commercials," Mr. Rieveley said. Sucanon is a new drug for treating symptoms of Type II Diabetes and Impaired Glucose Tolerance. The drug, in tablet form, works by improving patients' ability to utilize insulin, the hormone that controls blood sugar levels. Type II Diabetes affects more than 17 million people in North America and over 20 million in Latin America. In addition, the number of people with Impaired Glucose Tolerance is even larger than the number of diabetics. Biotech Holdings has received regulatory approval for sale of the drug in Mexico and Peru and plans to make regulatory applications for the drug for Chile, Venezuela, Colombia, Argentina and Brazil. If you would you would like to be added to Biotech Holdings' email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp Biotech Holdings Ltd.'s head office is in Richmond, British Columbia. Biotech Holdings' shares trade on the Over the Counter Bulletin Board in the United States (BIOHF.OB) and on the TSX Venture Exchange in Canada (BIO.V). For further information: Contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com SOURCE Biotech Holdings Ltd. -0- 09/22/2004 /CONTACT: contact Austin Rand at Biotech Holdings Ltd., 1 888 216 1111 (toll-free), 8:00 a.m. to 4 p.m. Pacific time, or by e-mail at biotech@direct.ca. For background information and current stock quotations, please visit Biotech's website at www.biotechltd.com; To request a free copy of this organization's annual report, please go to http://www.newswire.ca and click on reports@cnw./ (BIO. BIOHF) CO: Biotech Holdings Ltd. ST: British Columbia IN: MTC OTC SU: PDT -30-

Posts: 443 | From: Honolulu, HI | Registered: Jan 2004  |  IP: Logged |